Shuttle Pharmaceuticals

IN THE PRESS

Press Releases

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

November 14, 2024

·

6 min read

Press Releases

Shuttle Pharma Pays Off Senior Secured Convertible Note

October 30, 2024

·

4 min read

Press Releases

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

October 30, 2024

·

4 min read

Press Releases

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

October 29, 2024

·

4 min read

Press Releases

Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024

October 28, 2024

·

2 min read

Press Releases

Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease

September 5, 2024

·

3 min read

Press Releases

Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

August 28, 2024

·

2 min read

Press Releases

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

August 27, 2024

·

3 min read

Press Releases

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

August 15, 2024

·

4 min read

Press Releases

Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

July 19, 2024

·

3 min read

JOBS